Who is recommended to use Militizumab? What patient groups is it suitable for?

Mirikizumab is a humanized monoclonal antibody targeting the IL-23p19 subunit. It is mainly used to treat inflammatory bowel disease, especially moderately to severely active ulcerative colitis (UC). The drug regulates the immune system response and reduces intestinal mucosal inflammation by inhibiting the activity of interleukin 23 (IL-23), which has significant effects on relieving symptoms and promoting mucosal healing. Its launch provides a new targeted treatment option for patients with ulcerative colitis, especially for patients who are ineffective or intolerant to traditional treatments.

Milizumab is mainly recommended for patients with moderate to severe ulcerative colitis who have poor response to conventional treatments, including those who are ineffective or intolerant to glucocorticoids, biologics (such as anti-TNF-α drugs) or small molecule oral immunomodulators (such as tofacitinib). These patients often have protracted disease and frequent attacks, and it is difficult to control the disease with traditional treatments. Milizumab brings new hope to these refractory patients by specifically inhibiting the IL-23 signaling pathway.

In addition, militizumab has also shown good mucosal healing rates and the ability to maintain remission in clinical studies, making it suitable for UC patients who require long-term maintenance treatment. It can not only significantly relieve symptoms such as diarrhea, bloody stools, and abdominal pain, but also effectively improve the quality of life. Militizumab is an option worth considering for patients who wish to reduce steroid dependence and seek longer-lasting control.

However, not all patients are candidates for militizumab. Mild patients who have not been clearly diagnosed with moderate to severe active ulcerative colitis, those with active infection, those with severe immunodeficiency, and those allergic to the active ingredients of this product should use this drug with caution or be prohibited from using it. Before starting treatment, doctors usually conduct a comprehensive evaluation, including infection screening (such as tuberculosis, hepatitis B virus), liver and kidney function tests, etc., to ensure the safety of medication. Only when used scientifically under the guidance of professional doctors and based on individual conditions can the therapeutic benefits of militizumab be maximized.

Reference materials:https://omvoh.lilly.com/